What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma

View Full Paper

Ask AI

Bookmark

Estimated median response duration reached 73% at 12 months post-discontinuation in relapsed/refractory multiple myeloma patients.
This ongoing non-inferiority study analyzed clinical outcomes following limited-duration teclistamab treatment and discontinuation based on treatment response.
Participants achieving very good partial response had a median age of 73 years, with varied high-risk cytogenetic abnormalities identified.
These results imply that discontinuation could reduce long-term toxicities while maintaining similar efficacy compared to continuous therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Non-inferiority study shows 77% progression-free survival at 6 months in patients with relapsed multiple myeloma, suggesting discontinuation may be viable.

Cite This Study

Chakraborty et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de33 https://doi.org/10.1182/blood-2025-5814

View Full Paper

Ask AI

Bookmark

Implication

Non-inferiority study shows 77% progression-free survival at 6 months in patients with relapsed multiple myeloma, suggesting discontinuation may be viable.

Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma

Key Points

Discussion

Implication

Cite This Study

Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider